PERSPECTA

News from every angle

← Back to headlines

LeonaBio Exceeds Q2 Loss Forecast as ELAINE-3 Trial Progresses

LeonaBio has surpassed its second-quarter loss forecast, indicating better-than-expected financial performance. This positive outcome is attributed to the advancement of its Phase 3 ELAINE-3 trial.

17 Aug, 12:26 — 17 Aug, 12:26
PostShare

Sources

Showing 1 of 2 sources
YahooMostly Factual8d ago

LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances

Read full article →

Coverage Timeline

First report: investing-com · 17 Aug, 10:26Full coverage: 2 · 2hWindow: 2h
Left-leaningCenterRight-leaning
investing-com17 Aug, 10:26First to report

LeonaBio beats second quarter loss estimates - Investing.com

2h later
Yahoo17 Aug, 12:26Latest update

LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances

Related Stories

Canada Imposes Retaliatory Tariffs on US Goods Amid Trade Dispute

20m ago

Should Borrowers Switch from Floating to Fixed Home Loans Now?

25m ago

Nvidia Stock Volatility Ahead of Q2 Earnings Report

26m ago

US Home Sales Drop Amid Rising Prices and Mortgage Rates

27m ago